Price of Gilead’s Sovaldi expected at KRW 30 million in negotiation
The company seems to drop greediness. It was observed that Gilead will decide the price of ‘Sovaldi,’ a hepatitis C treatment approved domestically on the last 10th, at a lower price than the ones in other countries.
What has been observed is approximately KRW 30 million(the price after completi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
